HIV-1 RNA检测方法选择对低水平病毒血症及临床试验终点解读的影响
该研究评估Roche cobas 6800与Abbott RealTime HIV-1 RNA检测在两项进行中的多中心3b期试验中的一致性。对病毒学抑制或启动ART的成人配对血浆样本进行重新检测,发现在50和200 copies/mL阈值附近两种检测方法存在明显不一致,强调检测方法特异性解读低水平病毒血症的重要性。
要点
- 在cobas 6800结果≥50 copies/mL的样本中,RealTime检测显示病毒学抑制组92%低于50 copies/mL,启动ART组68%低于50 copies/mL。
- 在cobas 6800结果≥200 copies/mL的样本中,RealTime检测显示病毒学抑制组78%低于200 copies/mL,启动ART组83%低于200 copies/mL。
- 两种检测方法在临床相关低HIV-1 RNA阈值附近存在明显不一致,需按检测方法特异性解读低水平病毒血症。
核心结论
- 在临床相关低HIV-1 RNA阈值附近观察到两种检测方法之间存在明显不一致。
- 这些发现强调在临床试验和常规诊疗中按检测方法特异性解读低水平病毒血症的重要性,尤其是在决策阈值附近。
研究设计与样本
- 评估Roche cobas 6800与Abbott RealTime HIV-1 RNA检测在两项进行中的多中心3b期试验中的一致性。
- 使用病毒学抑制或启动ART的成人HIV-1感染者储存的配对血浆样本,分别为271和348对,样本选择包括预设关键研究访视的所有标本,并富集了中心报告的cobas 6800结果≥50 copies/mL的样本。
- 在临床相关分类阈值(50和200 copies/mL)评估一致性。
主要发现
- 在cobas 6800 HIV-1 RNA结果≥50 copies/mL的样本中,病毒学抑制组92%(91/99)和启动ART组68%(159/233)的样本经RealTime检测<50 copies/mL。
- 在cobas 6800 HIV-1 RNA结果≥200 copies/mL的样本中,病毒学抑制组78%(14/18)和启动ART组83%(44/53)的样本经RealTime检测<200 copies/mL。
- 大多数经cobas 6800分类为<50 copies/mL的样本经RealTime检测也<50 copies/mL。
- 所有经cobas 6800分类为<200 copies/mL的样本经RealTime检测也<200 copies/mL。
- 在两项研究中,按方案病例审查发现大多数病毒血症病例无临床相关因素。
临床怎么用
- 在临床试验和常规诊疗中解读低水平病毒血症时,应考虑所用HIV-1 RNA检测方法的特异性,尤其在50和200 copies/mL等决策阈值附近。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate plasma HIV-1 viral load quantification is essential for monitoring responses to antiretroviral therapy (ART) and defining efficacy in clinical trials. Differences in assay performance characteristics may result in discordant results and affect clinical interpretation. We evaluated concordance between the Roche cobas 6800 and Abbott RealTime HIV-1 RNA assays in 2 ongoing, multicenter, phase 3b trials. METHODS: Stored paired plasma aliquots from adults with HIV-1 who were virologically suppressed or initiating ART (271 and 348 paired samples, respectively) were batch re-tested using the RealTime assay; sample selection included all specimens from pre-specified key study visits and was enriched for selected centrally reported cobas 6800 results ≥50 copies/mL. Concordance was evaluated at clinically relevant categorical thresholds (50 and 200 copies/mL). RESULTS: Overall, among samples with cobas 6800 HIV-1 RNA results ≥50 copies/mL, 92% (91/99) of samples from participants who were virologically suppressed and 68% (159/233) from participants initiating ART were <50 copies/mL by RealTime. Among samples with cobas 6800 HIV-1 RNA results ≥200 copies/mL, 78% (14/18) and 83% (44/53), respectively, were <200 copies/mL by RealTime. Most samples classified as <50 copies/mL by cobas 6800 were <50 copies/mL by RealTime. All samples classified as <200 copies/mL by cobas 6800 were <200 copies/mL by RealTime. In both studies, per-protocol case review identified no clinical contributors in most cases of viremia. CONCLUSIONS: Marked discordance between assays was observed near clinically relevant low HIV-1 RNA thresholds. These findings highlight the importance of assay-specific interpretation of low-level viremia in trials and routine care, particularly near decision-making thresholds.
引用
- Geretti AM, Wang K, Leverette B, et al. Impact of HIV-1 RNA Assay Selection on Low-Level Viremia and Clinical Trial Endpoint Interpretations. Clin Infect Dis. 2026. PMID: 42461310. doi:10.1093/cid/ciag435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。